ATCT-15 CB-018: A PHASE 2 TRIAL OF BEVACIZUMAB PLUS TPI 287, A NOVEL BRAIN PENETRABLE ANTI-MICROTUBULE AGENT, IN PATIENTS WITH RECURRENT GLIOBLASTOMA FOLLOWING PROGRESSION ON ANTI-ANGIOGENIC THERAPY

Схожие документы

• ATNT-08 CB-017: A PHASE 1/2 TRIAL OF BEVACIZUMAB PLUS TPI 287, A NOVEL BRAIN PENETRABLE ANTI-MICROTUBULE AGENT, IN PATIENTS WITH RECURRENT GLIOBLASTOMA NAÏVE TO ANTI-ANGIOGENIC THERAPY
  по: Goldlust, Samuel, et al.
  Опубликовано: (2015)
• ACTR-28. FINAL RESULTS FROM THE DOSE-ESCALATION STAGE OF A PHASE 1/2 TRIAL OF TPI 287, A BRAIN PENETRABLE MICROTUBULE INHIBITOR, PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
  по: Goldlust, Samuel, et al.
  Опубликовано: (2017)
• AT-24 PHASE 1/2 TRIAL OF BEVACIZUMAB PLUS TPI 287, A NOVEL BRAIN PENETRABLE ANTI-MICROTUBULE AGENT, FOR THE TREATMENT OF RECURRENT GLIOBLASTOMA
  по: Goldlust, Samuel, et al.
  Опубликовано: (2014)
• TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
  по: Fitzgerald, Daniel P., et al.
  Опубликовано: (2012)
• A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma
  по: McQuade, Jennifer L., et al.
  Опубликовано: (2016)